MCID: ESN014
MIFTS: 36

Eosinophilic Enteropathy

Categories: Gastrointestinal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Eosinophilic Enteropathy

MalaCards integrated aliases for Eosinophilic Enteropathy:

Name: Eosinophilic Enteropathy 54 74
Eosinophilic Gastroenteritis 54 74
Eosinophilic Esophagitis 54 74
Eosinophilic Gastritis 54 74
Eosinophilic Gastroenteropathy 54
Eosinophilic Enteritis 54

Classifications:



External Ids:

Summaries for Eosinophilic Enteropathy

NIH Rare Diseases : 54 Eosinophilic enteropathy is a condition that causes a type of white blood cell called an eosinophil to build up in the gastrointestinal system and in the blood. Eosinophils play a role in the body�??s immune response by releasing toxins. Eosinophils are associated with allergic-type reactions, but their specific function is largely unknown.When eosinophils build up in the gastrointestinal tract, this begins to affect the body by causing polyps, tissue break down, inflammation, and ulcers. Eosinophilic enteropathy can occur in children or adults and is characterized by intolerance to some foods. Eosinophilic enteropathy can affect any part of the gastrointestinal tract, and is often named by the part affected: colon (colitis), esophagus (esophagitis), stomach (gastritis), or both the stomach and small intestine (gastroenteritis).

MalaCards based summary : Eosinophilic Enteropathy, also known as eosinophilic gastroenteritis, is related to esophagitis, eosinophilic, 1 and eosinophilic gastritis, and has symptoms including vomiting and epigastric pain. The drugs Fluticasone and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include colon, small intestine and testes.

Related Diseases for Eosinophilic Enteropathy

Diseases related to Eosinophilic Enteropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 160)
# Related Disease Score Top Affiliating Genes
1 esophagitis, eosinophilic, 1 12.6
2 eosinophilic gastritis 11.7
3 esophagitis 11.3
4 eosinophilic gastroenteritis 11.3
5 autosomal dominant intellectual disability 30 11.2
6 gastroesophageal reflux 10.5
7 dysphagia 10.5
8 hypereosinophilic syndrome 10.5
9 food allergy 10.5
10 celiac disease 1 10.4
11 pancreatitis 10.3
12 gastroenteritis 10.3
13 proton-pump inhibitor-responsive esophageal eosinophilia 10.3
14 tracheoesophageal fistula with or without esophageal atresia 10.2
15 esophageal atresia 10.2
16 asthma 10.2
17 duodenal ulcer 10.2
18 acute pancreatitis 10.2
19 ige responsiveness, atopic 10.2
20 barrett esophagus 10.2
21 myositis 10.2
22 duodenal obstruction 10.2
23 achalasia 10.1
24 jackhammer esophagus 10.1
25 obstructive jaundice 10.1
26 cystitis 10.1
27 intestinal obstruction 10.1
28 eosinophilic cystitis 10.1
29 peptic esophagitis 10.1
30 crohn's disease 10.0
31 herpes simplex 10.0
32 intussusception 10.0
33 systemic lupus erythematosus 10.0
34 hypereosinophilic syndrome, idiopathic 10.0
35 ileocolitis 10.0
36 gastric ulcer 10.0
37 churg-strauss syndrome 10.0
38 lupus erythematosus 10.0
39 polyarteritis nodosa 10.0
40 allergic angiitis 10.0
41 eosinophilic granulomatosis with polyangiitis 10.0
42 diarrhea 10.0
43 allergic rhinitis 10.0
44 colitis 10.0
45 pollen allergy 10.0
46 allergic hypersensitivity disease 10.0
47 rhinitis 10.0
48 gastrointestinal system disease 10.0
49 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.0
50 keratomalacia 10.0

Graphical network of the top 20 diseases related to Eosinophilic Enteropathy:



Diseases related to Eosinophilic Enteropathy

Symptoms & Phenotypes for Eosinophilic Enteropathy

UMLS symptoms related to Eosinophilic Enteropathy:


vomiting, epigastric pain

Drugs & Therapeutics for Eosinophilic Enteropathy

Drugs for Eosinophilic Enteropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
2
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 5281004 63006
3
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
4
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005
5
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
6 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Cromolyn Sodium Phase 4
18 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Not Applicable
20 Soy Bean Phase 4,Phase 2,Phase 3,Not Applicable
21 Olive Phase 4
22 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
23 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
24 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
25 Proton Pump Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
26
Montelukast Approved Phase 3,Phase 1,Not Applicable 158966-92-8 5281040
27 Reslizumab Approved, Investigational Phase 3,Phase 2
28
Esomeprazole Approved, Investigational Phase 2, Phase 3,Not Applicable 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
29
Histamine Approved, Investigational Phase 3 51-45-6 774
30
Ketotifen Approved Phase 3 34580-14-8, 34580-13-7 3827
31 Leukotriene Antagonists Phase 3,Phase 1,Not Applicable
32 Antibodies Phase 3,Phase 2,Phase 1
33 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
34 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
35 Immunoglobulins Phase 3,Phase 2,Phase 1
36 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
37 Antipruritics Phase 3,Not Applicable
38 Histamine Antagonists Phase 3
39
Histamine Phosphate Phase 3 51-74-1 65513
40 Histamine H1 Antagonists Phase 3
41
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
42
Infliximab Approved Phase 2 170277-31-3
43
Benzocaine Approved, Investigational Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
44
tannic acid Approved Phase 2,Not Applicable 1401-55-4
45 Benralizumab Approved, Investigational Phase 1, Phase 2 1044511-01-4
46
Losartan Approved Phase 2 114798-26-4 3961
47
Angiotensin II Approved, Investigational Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
48
Bethanechol Approved Phase 2 674-38-4 2370
49
mometasone furoate Approved, Investigational, Vet_approved Phase 2 83919-23-7
50 Caseins Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 140)
# Name Status NCT ID Phase Drugs
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
3 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
4 EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
5 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
6 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
7 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3 reslizumab
8 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
9 A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Completed NCT02605837 Phase 3 Oral Budesonide Suspension (OBS);Placebo
10 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
11 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed NCT02610816 Phase 2, Phase 3 Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
12 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3 Fluticasone Propionate
13 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
14 Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
15 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Recruiting NCT03633617 Phase 3 Dupilumab;Placebo
16 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3 Flovent
17 Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia Recruiting NCT02484248 Phase 3 Ketotifen;Placebo
18 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Active, not recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
19 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
20 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Completed NCT00762073 Phase 2 budesonide;placebo
21 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
22 Budesonide for Eosinophilic Esophagitis Completed NCT00271349 Phase 2 Budesonide
23 Milk Patch for Eosinophilic Esophagitis Completed NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
24 Topical Steroid Treatment for Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
25 Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
26 Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
27 Proof of Concept Study of OC000459 in Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
28 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
29 Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
30 Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
31 Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) Completed NCT02379052 Phase 2 Dupilumab;Placebo
32 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
33 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
34 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
35 Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
36 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed NCT00358449 Phase 2 mepolizumab
37 Omalizumab to Treat Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
38 An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients Completed NCT00274703 Phase 2 mepolizumab
39 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
40 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
41 Benralizumab for Eosinophilic Gastritis Recruiting NCT03473977 Phase 1, Phase 2
42 A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Recruiting NCT03496571 Phase 2 AK002
43 Mepo for EoE Study Recruiting NCT03656380 Phase 2 Mepolizumab 300 mg;Mepolizumab 100 mg
44 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Active, not recruiting NCT01821898 Phase 2 Oral Budesonide
45 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03191864 Phase 2 APT-1011;Placebo
46 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03029091 Phase 2 Losartan Potassium
47 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
48 An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Enrolling by invitation NCT03664960 Phase 2 AK002
49 DEGS - Dupilumab for Eosinophilic Gastritis Study Not yet recruiting NCT03678545 Phase 2 Dupilumab (blinded);Placebo (blinded);Dupilumab (open-label)
50 Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis Not yet recruiting NCT02873468 Phase 2 Florence 30 μg/mL;Florence 60 μg/mL;Florence 90 μg/mL

Search NIH Clinical Center for Eosinophilic Enteropathy

Genetic Tests for Eosinophilic Enteropathy

Anatomical Context for Eosinophilic Enteropathy

MalaCards organs/tissues related to Eosinophilic Enteropathy:

42
Colon, Small Intestine, Testes, Bone, Liver, T Cells, Bone Marrow

Publications for Eosinophilic Enteropathy

Articles related to Eosinophilic Enteropathy:

(show top 50) (show all 434)
# Title Authors Year
1
Eosinophilic Gastroenteritis Presenting With Gastric Perforation. ( 29366927 )
2019
2
Eosinophilic gastroenteritis: An unusual presentation of a rare disease. ( 29555104 )
2019
3
Clinical and pathological profile of eosinophilic gastroenteritis. ( 30113369 )
2019
4
Abdominal ascites in children as the presentation of eosinophilic gastroenteritis: A surgeon's perspective. ( 30528318 )
2019
5
A Case of Eosinophilic Gastroenteritis Associated with Eosinophilic Ascites Diagnosed by Full-Thickness Biopsy of the Small Intestine. ( 30755542 )
2019
6
Abnormal thymic stromal lymphopoietin expression in the gastrointestinal mucosa of patients with eosinophilic gastroenteritis. ( 30763528 )
2019
7
Modified oral enteric-coated budesonide regimens to treat pediatric eosinophilic gastroenteritis, a single center experience. ( 30763733 )
2019
8
Clinical features and treatment outcomes of eosinophilic gastroenteritis : an analysis of 28 cases. ( 30888747 )
2019
9
Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. ( 30982212 )
2019
10
Endoscopic Features and Diagnostic Procedures of Eosinophilic Gastroenteritis. ( 30996166 )
2019
11
Efficacy of an elimination diet in a patient with eosinophilic gastroenteritis : a pediatric case with multiple food allergies. ( 31064942 )
2019
12
Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab. ( 30056148 )
2018
13
Eosinophilic gastroenteritis complicating acute calculus eosinophilic cholecystitis 6 months after cholecystectomy. ( 30370999 )
2018
14
Eosinophilic Gastroenteritis and Colitis: Not Yet Ready for the Big Leagues. ( 29620603 )
2018
15
Post-partum eosinophilic gastroenteritis: A case report. ( 28081983 )
2018
16
A Prospective Study on the Prevalence, Extent of Disease and Outcome of Eosinophilic Gastroenteritis in Patients Presenting with Lower Abdominal Symptoms. ( 29212311 )
2018
17
Eosinophilic Gastroenteritis in Which Obstructive Jaundice Developed due to Invagination of the Duodenal Wall. ( 29434146 )
2018
18
Eosinophilic gastroenteritis and other eosinophilic gut diseases distal to the oesophagus. ( 29533199 )
2018
19
Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis. ( 29596982 )
2018
20
Successful Food-Elimination Diet in an Adult with Eosinophilic Gastroenteritis. ( 29850645 )
2018
21
Ascites in a Young Woman: A Rare Presentation of Eosinophilic Gastroenteritis. ( 29862093 )
2018
22
Takayasu's arteritis associated with eosinophilic gastroenteritis, possibly via the overactivation of Th17. ( 29942355 )
2018
23
Massive hemorrhagic ascites: A rare presentation of eosinophilic gastroenteritis. ( 30079343 )
2018
24
Prevalence of Eosinophilic Gastroenteritis and Colitis in a Population-Based Study, From 2012 to 2017. ( 28603057 )
2017
25
Eosinophilic Enteropathy Presenting as Small Bowel Obstruction. ( 30454227 )
2017
26
Eosinophilic gastroenteritis: A state-of-the-art review. ( 27253425 )
2017
27
Eosinophilic gastroenteritis in a teenager: A rare diagnosis. ( 27283450 )
2017
28
Eosinophilic gastroenteritis: three clinical cases with different presentations. ( 28063615 )
2017
29
Eosinophilic Gastroenteritis Presenting with Red Streaking. ( 28250308 )
2017
30
Eosinophilic gastroenteritis caused by eating hens' eggs: A case report. ( 28279648 )
2017
31
Hematemesis as Initial Presentation in a 10-Week-Old Infant with Eosinophilic Gastroenteritis. ( 28299223 )
2017
32
CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis. ( 28497923 )
2017
33
Diagnosis of eosinophilic gastroenteritis is easily missed. ( 28596692 )
2017
34
Lack of Knowledge and Low Readiness for Health Care Transition in Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 28644350 )
2017
35
Eosinophilic gastroenteritis presenting as upper gastrointestinal hematoma and ulcers after endoscopic biopsy: A case report and literature review. ( 28906408 )
2017
36
Serum Biomarkers for the Diagnosis of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis. ( 28943560 )
2017
37
Eosinophilic Ascites: Uncommon Presentation of Eosinophilic Gastroenteritis in a Young Adult Male. ( 29255753 )
2017
38
Eosinophilic Ascites-Rarest Presentation of a Rare Disease, Eosinophilic Gastroenteritis. ( 29313586 )
2017
39
Eosinophilic gastroenteritis; a report of two cases with different presentations. ( 29511487 )
2017
40
Subserous Eosinophilic Gastroenteritis: A Rare Cause of Ascites. ( 30755942 )
2017
41
Severe Eosinophilic Gastroenteritis in a Crohn's Disease Patient Treated With Infliximab and Adalimumab. ( 27018120 )
2016
42
A Case of Eosinophilic Gastroenteritis Forming a Rigid Chamber Mimicking Giant Duodenal Ulcer on Computed Tomography Imaging. ( 27086704 )
2016
43
Eosinophilic Esophagitis, Eosinophilic Gastroenteritis, and Eosinophilic Colitis: Common Mechanisms and Differences between East and West. ( 29922659 )
2016
44
Ileoileal Intussusceptions Caused by Eosinophilic Enteropathy. ( 25000350 )
2016
45
Eosinophilic Gastroenteritis and Colitis: a Comprehensive Review. ( 26054822 )
2016
46
Severe eosinophilic gastroenteritis. ( 26802190 )
2016
47
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency. ( 26840762 )
2016
48
Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL-33 levels. ( 26948075 )
2016
49
Eosinophilic Gastroenteritis: An Underdiagnosed Condition. ( 27234270 )
2016
50
Eosinophilic Gastroenteritis as a Rare Cause of Recurrent Epigastric Pain. ( 27274524 )
2016

Variations for Eosinophilic Enteropathy

Expression for Eosinophilic Enteropathy

Search GEO for disease gene expression data for Eosinophilic Enteropathy.

Pathways for Eosinophilic Enteropathy

GO Terms for Eosinophilic Enteropathy

Sources for Eosinophilic Enteropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....